Key result
Genetic and pharmacological ablation of cIAP1 significantly attenuated denervation-induced skeletal muscle atrophy by inhibiting the IKKβ/NF-κB/MuRF1 signaling pathway.
Why the study?
NF-κB targeting drugs are not currently used to treat skeletal muscle atrophy, likely due to limited knowledge and specificity for muscle biology, while cIAP1 regulates NF-κB signaling.
Absolute Event Rate: 12% vs 64%
p-value: p=<0.05
Targeted ablation of cIAP1 attenuates denervation-induced skeletal muscle atrophy, identifying it as a potential therapeutic target for muscle wasting diseases.
Supports cIAP1 inhibition in preclinical denervation models; hypothesis-generating for muscle wasting, requiring clinical validation before practice change.
BACKGROUND: Skeletal muscle atrophy is a pathological condition that contributes to morbidity in a variety of conditions including denervation, cachexia, and aging. Muscle atrophy is characterized as decreased muscle fiber cross-sectional area and protein content due, in part, to the proteolytic activities of two muscle-specific E3 ubiquitin ligases: muscle RING-finger 1 (MuRF1) and muscle atrophy F-box (MAFbx or Atrogin-1). The nuclear factor-kappa B (NF-κB) pathway has emerged as a critical signaling network in skeletal muscle atrophy and has become a prime therapeutic target for the treatment of muscle diseases. Unfortunately, none of the NF-κB targeting drugs are currently being used to treat these diseases, likely because of our limited knowledge and specificity, for muscle biology and disease. The cellular inhibitor of apoptosis 1 (cIAP1) protein is a positive regulator of tumor necrosis factor alpha (TNFα)-mediated classical NF-κB signaling, and cIAP1 loss has been shown to enhance muscle regeneration during acute and chronic injury. METHODS: Sciatic nerve transection in wild-type, cIAP1-null and Smac mimetic compound (SMC)-treated mice was performed to investigate the role of cIAP1 in denervation-induced atrophy. Genetic in vitro models of C2C12 myoblasts and primary myoblasts were also used to examine the role of classical NF-κB activity in cIAP1-induced myotube atrophy. RESULTS: We found that cIAP1 expression was upregulated in denervated muscles compared to non-denervated controls 14 days after denervation. Genetic and pharmacological loss of cIAP1 attenuated denervation-induced muscle atrophy and overexpression of cIAP1 in myotubes was sufficient to induce atrophy. The induction of myotube atrophy by cIAP1 was attenuated when the classical NF-κB signaling pathway was inhibited. CONCLUSIONS: These results demonstrate the cIAP1 is an important mediator of NF-κB/MuRF1 signaling in skeletal muscle atrophy and is a promising therapeutic target for muscle wasting diseases.
No takes yet. Share an insight, caveat, or question.
Lala-Tabbert et al. (2019) studied Skeletal muscle atrophy. Targeted ablation of cIAP1 (genetic or pharmacological with LCL161) vs. Wild-type mice or vehicle was evaluated on Decrease in mean fiber cross-sectional area of the tibialis anterior (TA) muscle after denervation (p=<0.05). Genetic and pharmacological ablation of cIAP1 significantly attenuated denervation-induced skeletal muscle atrophy by inhibiting the IKKβ/NF-κB/MuRF1 signaling pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: